Related Experiment Video

Updated: May 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer

Ryo Yoriki1, Satoru Akashi, Masayuki Sho

  • 1Department of Surgery, Nara Medical University, Nara;

Experimental and Therapeutic Medicine
|September 15, 2012
PubMed

Insights

The TWEAK/Fn14 pathway is crucial in esophageal and pancreatic cancers. Blocking TWEAK or Fn14 shows therapeutic potential, inhibiting tumor growth in preclinical models, suggesting novel anti-cancer strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a pro-inflammatory cytokine.
  • Fibroblast growth-inducible 14 (Fn14) is the TWEAK receptor.
  • The TWEAK-Fn14 pathway is implicated in cell growth, apoptosis, and angiogenesis.

Purpose of the Study:

  • To investigate the role of the TWEAK/Fn14 pathway in esophageal and pancreatic cancers.
  • To evaluate TWEAK and Fn14 as potential molecular targets for anti-cancer therapy.

Main Methods:

  • Immunohistochemistry to assess TWEAK and Fn14 protein expression in patient tumor tissues.
  • Gene expression analysis in esophageal and pancreatic cancer cell lines.
  • In vitro tumor growth inhibition assays using anti-TWEAK or anti-Fn14 monoclonal antibodies (mAbs).
  • In vivo studies using a murine gastrointestinal cancer model.

Main Results:

  • TWEAK or Fn14 expression was detected in 58.1% of esophageal and 74.5% of pancreatic cancer cases.
  • TWEAK/Fn14 gene expression was prevalent in human esophageal and pancreatic cancer cell lines.
  • Anti-TWEAK or anti-Fn14 mAb treatment inhibited cancer cell growth by 22-65% in vitro.
  • Targeting the TWEAK/Fn14 pathway demonstrated significant therapeutic effects in vivo.

Conclusions:

  • The TWEAK/Fn14 pathway is potentially functional and critical in esophageal and pancreatic cancers.
  • TWEAK and/or Fn14 represent promising novel molecular targets for anti-cancer therapies.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...